Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series
- 01.02.2020
- Original Article – Clinical Oncology
Erschienen in:
- Verfasst von
- Christoph Oing
- Marcus Hentrich
- Anja Lorch
- Dietrich Gläser
- Holger Rumpold
- Sebastian Ochsenreither
- Stephan Richter
- Annette Dieing
- Stefanie Zschäbitz
- Ronnie Rodrigues Pereira
- Carsten Bokemeyer
- Christoph Seidel
- Erschienen in
- Journal of Cancer Research and Clinical Oncology | Ausgabe 2/2020
Abstract
Purpose
Outcomes of multiply relapsed, refractory germ-cell tumour (GCT) patients remain poor with an overall survival (OS) of a few months only. Thus, new therapeutic advances are urgently needed. Cabazitaxel has shown preclinical activity in platinum-resistant GCT models. Here, we report the first clinical case series of cabazitaxel treatment for platinum-refractory GCT.
Methods
Data of multiply relapsed GCT patients receiving single-agent cabazitaxel were retrospectively analysed. Endpoints included 12-week progression-free survival (PFS) rate, disease control rate, tumour marker responses, median PFS and OS, and toxicity.
Results
Cabazitaxel showed limited activity in 13 heavily pre-treated GCT patients. After a median follow-up of 23 weeks (IQR 29), 69% of patients were deceased. A median of 2 cycles of cabazitaxel (range 1–7) were applied. The 12-week PFS rate was 31%. Median PFS and OS were 7 and 23 weeks, respectively. Two patients achieved objective responses (15%), three patients (23%) achieved a tumour marker decline ≥ 50%, and the disease control rate was 39%. Cabazitaxel was well tolerated. CTCAE° III–IV haemato-toxicity was most common (54%), and dose reductions were scarce (15%).
Conclusion
In this case series, cabazitaxel showed limited activity in heavily pre-treated GCT patients. Two-phase II studies are underway (NCT02115165, NCT02478502) prospectively assessing cabazitaxel in multiply relapsed GCTs.
Anzeige
- Titel
- Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series
- Verfasst von
-
Christoph Oing
Marcus Hentrich
Anja Lorch
Dietrich Gläser
Holger Rumpold
Sebastian Ochsenreither
Stephan Richter
Annette Dieing
Stefanie Zschäbitz
Ronnie Rodrigues Pereira
Carsten Bokemeyer
Christoph Seidel
- Publikationsdatum
- 01.02.2020
- Verlag
- Springer Berlin Heidelberg
- Erschienen in
-
Journal of Cancer Research and Clinical Oncology / Ausgabe 2/2020
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335 - DOI
- https://doi.org/10.1007/s00432-019-03071-2
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
